$75 Million

Dynavax Technologies Corp

Follow-on Offering

Lead Left Bookrunner, August 2017

Dynavax Technologies Corp
Dynavax Technologies is a clinical-stage biopharmaceutical company developing products to prevent and treat infectious and inflammatory diseases and cancer. The Company is focused on leveraging the body's innate and adaptive immune response through toll-like receptor (TLR) stimulation. Dynavax's lead product candidate, HEPLISAV, is a BLA-filed investigational adult hepatitis B vaccine. HEPLISAV combines the Company's proprietary TLR 9 agonist adjuvant and hepatitis B surface antigen to elicit an immune response after two doses.